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The natural history of transmission transfusion virus 
(TTV) infection has not been precisely delineated. 
Previously published data show that TTV infection may 
be acquired early in life, particularly in countries with 
high prevalence rates in the general population.’ It was 
shown that TTV infection is present worldwide among 
blood donors, ranging from 1% in Taiwan, to 62% in 
Brazil.’ In Egypt, the reported incidence is 29%.2 
The incidence of TTV in different liver diseases 
is also variable: 2946% in acute hepatitis, 47-71% in 
chronic hepatitis, 9.2-30% in hepatocellular carcinoma 
(HCC), and 63% in patients with cirrhosis.’ However, 
TTV has also been found in association with many other 
diseases, such as bilharziasis,* renal failure (RF), and 
beta-thalassemia,3 and in patients exposed to repeated 
blood transfusion4 However, the significance of this viral 
association is not yet clarified yet. 
Therefore, the present study was conducted to 
determine the pattern of TTV infection in six groups of 
Egyptian patients with HCC, bilharziasis, hepatitis C 
virus (HCV)-associated chronic active hepatitis (CAH), 
Hodgkin’s disease (HD), RF and diabetes mellitus (DM), 
in addition to a group of healthy blood donors (HBDs) 
negative for both hepatitis B virus (HBV) and HCV. 
The study included six groups of patients (n=204) 
-37 HCC, 30 RF, 30 HD, 30 DM (22 non-insulin- 
dependent DM (NIDDM) and eight insulin-dependent 
DM (IDDM)), 30 CAH with HCV and 47 bilharziasis 
patients-who attended the National Cancer Institute, 
Cairo University, Ain Shams University Hospital and 
Theodore Bilhars Institute during 1998-2000. Also, 31 
HBDs negative for all HBV and HCV markers were 
included. 
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The routine workup of patients included: (1) detailed 
history (blood transfusion, surgical procedures, liver 
cirrhosis, periportal fibrosis, or hepatosplenomegaly); (2) 
thorough clinical examination; (3) abdominal ultrasound 
(US) or computed tomography (CT); and (4) liver func- 
tion tests. 
Serum samples were tested for HbsAg, HbcAb 
and anti-HCV-Ab using enzyme immunoassay (EIA) 
(Abbott, North Chicago, IL, USA), and bilharzial anti- 
body by the indirect hemagglutination method (Labora- 
tories Fumoze, La Mulesherbes, France), according to 
the manufacturer’s instructions. 
HCV RNA was extracted as described by Boom et 
aL5 reverse transcriptaze and PCR were performed 
according to Zekri et al, 6 HBV was extracted and 
amplified as described by Boom et aL5 and detection of 
TTV was done according to Viazov et al.” 
Statistical analysis was done using the unpaired 
Student t-test (two-sided) for comparing two groups, an 
analysis of variance (F-test) for more than two groups, 
a post hoc test for comparing each two groups, and 
Fisher’s exact test for 2 x 2 tables. Significance levels of 
0.05 and 0.01 were used. 
TTV DNA was detected in 80% of the patients with 
RF, 76.7% with HD, 56.7% with HCC, 53.3% with DM 
and CAH (each), and 46.8% with bilharziasis, and in 
35.5% of HBDs (Table 1). 
Mixed infection of TTV and HCV was detected in 
16 of 30 RF cases, TTV and HBV in 10 cases, and TTV, 
HCV and HBV in three cases. In HD, mixed infections 
with TTV and HCV were present in seven of 30 cases, 
and TTV and HBV in 11 cases; one case had TTV, HCV, 
and HBV. Thirteen HCC cases had mixed infection with 
TTV and HCV, five had mixed infection with TTV and 
HBV, and one case harbored all three viruses. In DM, 
four of 30 cases had TTV and HCV, and nine had TTV 
and HBV Fourteen bilharzial cases had TTV and HCV, 
19 had TTV and HBV, and one had TTV, HCV, and 
HBV. 
All RF patients with elevated alanine amino- 
transferase (ALT) levels (17) were positive for HBV, 
HCV, or bilharziasis. Five HD patients had high ALT 
levels; four of them were TTV and HCV positive. In 
bilharzial patients, elevated ALT levels were found in 
19 cases; 15 of them were TTV positive. There were 
statistically significant differences between TTV-positive 
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Table 1. Viral profile of the studied groups 
Studied 
groups 
Anti-B-Ab 
Hbs-Ag 
Hbc-Ab 
HBVPCR 
HCV-Ab 
HCVPCR 
I-IVPCR 
Control 
2131 (6.5%) 
o/31 (0.0%) 
S/31 (16.1%) 
0131 (0.0%) 
o/31 (0.0%) 
o/31 (0.0%) 
11131 (35.5%) 
Bilharzia 
47147 (100%) 
13147 (27.6%) 
34147 (72.3%) 
S/47 (10.6%) 
20147 (42.5%) 
IO/47 (21.3%) 
22147 (46.8%) 
Diabetic 
2/30 (6.7%) 
2/30 (6.7%) 
14130 (46.7%) 
l/30 (3.3%) 
6/30 (20%) 
4/30 (13.3%) 
16/30 (53.3%) 
HD 
9/30 (30%) 
2/30 (6.7%) 
11/30 (36.7%) 
l/30 (3.3%) 
IO/30 (33.3%) 
7130 (23.3%) 
23130 (76.7%) 
RF CAH HCC 
15/30(50%) 
11130 (36.7%) 
15/30 (50%) 
8130 (26.7%) 
17/30 (56.6%) 
11/30 (36.7%) 
24/30 (80.0%) 
0130 (0%) 
o/30 (0.0%) 
o/30 (0.0%) 
0130 (0.0%) 
30/30 (100%) 
24130 (80%) 
16/30 (53.3%) 
14137 (37.8%) 
s/37 (13.5%) 
32/37 (86.5%) 
3/37 (8.1%) 
32137 (86.5%) 
21137 (56.8%) 
21/37(56.8%) 
and TIV-negative patients as follows: in CAH patients 
in the levels of alkaline phosphatase, total bilirubin, and 
total protein (P=O.OOl); in bilharzial patients in the 
levels of ALT, aspartate aminotransferase (AST), 
alkaline phosphatase, total bilirubin, total protein, a 
history of blood transfusion, presence of cirrhosis, and 
HCV association (P=O.OOS); in HD patients in the levels 
of albumin and associated HCV infection (P=O.O3); in 
DM patients in the levels of ALT, AST, associated HCV, 
and history of hepatosplenomegaly (P=O.O09); and in 
HCC cases in the level of HCV association only. RF 
patients and HBDs did not show any significant 
difference between both groups. 
Also, there was a statistically significant difference 
between patients with TTV only and those with TTV 
and HCV among DM and bilharzial patients with regard 
to ALT, AST, HCV association, history of blood trans- 
fusion, and hepatosplenomegaly (P=O.OOl). 
There was an obvious correlation between the degree 
of severity of cirrhosis in HCC cases and co-infection 
with TTV and HCV. 
The present study agrees with the results of Gad et 
al2 regarding the high prevalence of TTV (35.5%) in 
Egyptian HBDs. However, a higher incidence (81%) 
was reported by Abe et al7 that could be attributed to 
the types of blood donor, association with other types of 
infection, or the difference in the geographic areas from 
which samples were collected. 
The highest prevalence was reported in hemo- 
dialysis patients (80%). This high prevalence was also 
reported in Japan (51%), Brazil (53.8%) and Taiwan 
(61%).‘s3 This may reflect a high prevalence in the 
general population, a long period of hemodialysis, or 
repeated blood transfusion. However, some studies 
found no relationship between TTV infection and the 
period of dialysis or amount of blood transfused. We 
also agree with Gallian et al3 regarding the high pre- 
valence of TIV in anti-HBc-Ab-positive patients, which 
is a classical marker of parental exposure in RF. 
Our results regarding the high prevalence of TTV in 
HD are comparable to those of Maeda et a1.8 This could 
be attributed to repeated blood transfusions in these 
patients, or to the high prevalence of TTV infection in 
the African population.3 
Although we found a high prevalence of TTV 
infection in HCC patients, there was no significant 
difference between TTV-positive and TI’V-negative cases 
in the clinicopathologic features or the serum markers. 
This was also reported by Kato et al,9 who found no 
difference in the number, size or grade of tumors with 
TTV infection, providing evidence that TTV is not 
implicated in the progression of HCC. Moreover, it has 
been demonstrated that co-infection with TTV does not 
increase the risk of hepatocarcinogensis in chronic HCV 
and/or HBV patients.g 
Our high prevalence of TTV infection in diabetic 
patients agrees with previously reported data; 3 however, 
the significance and explanation of this finding are yet 
to be elucidated, since the relationship between TTV 
infection and DM is independent of the risk factors or 
superinfection with HCV. 
We agree with Gad et al2 that bilharziasis is not a 
risk factor for the acquisition of TIV infection, since the 
prevalence of TIV in bilharzial patients was comparable 
to that in HBDs.This also points to the presence of other 
routes of transmission of TTV besides the parenteral 
route. Fecal-oral transmission is a possible route in 
developing countries, and could explain the high pre- 
valence of TTV in HBDs who did not receive blood 
transfusions. 
The prevalence rate of TTV reported here in chronic 
liver diseases is within the reported range (12-62.5%).l 
Colombatto et ali0 reported TTV superinfection in 
35.7% and 32.1% of chronic hepatitis B and C patients 
respectively, which could be explained by the presence 
of common routes of transmission. 
Our results showed no significant difference between 
the prevalence of TTV DNA in patients with liver 
diseases and in the general population, indicating that 
the virus has no role as an etiologic factor in these 
patients. It was also shown that the presence of TTV in 
patients with chronic liver diseases has no influence on 
the end stage of liver disease, suggesting that it is a 
prevalent pathogen with little pathogenic effect.‘,’ We 
also found that TTV superinfection did not aggravate the 
damage induced by chronic HCV, HBV, HCV and HBV 
infection or correlate with the severity of HCV-positive 
liver disease. 
In conclusion, we demonstrated a high prevalence 
of TTV in the Egyptian population. The highest 
frequencies were detected in RF and HD patients. There 
were no significant differences in the prevalence of TTV 
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between different groups of patients or between these 
groups and HBDs. We also found a high prevalence rate 
of ITV in HCC. However, TTV infection did not affect 
the risk of HCC in HCV- or HBV-associated CAH, 
indicating that the virus plays a minor role, if any, in 
hepatocarcinogenesis. 
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